# Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori

> **NCT02422706** · PHASE3 · UNKNOWN · sponsor: **Sherief Abd-Elsalam** · enrollment: 120 (estimated)

## Conditions studied

- Helicobacter-associated Gastritis

## Interventions

- **DRUG:** Nitazoxanide
- **DRUG:** Metronidazole(MTZ)
- **DRUG:** Omeprazole
- **DRUG:** Clarithromycin
- **DRUG:** Levofloxacin
- **DRUG:** Doxicycline

## Key facts

- **NCT ID:** NCT02422706
- **Lead sponsor:** Sherief Abd-Elsalam
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-01
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2017-04-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02422706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02422706, "Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02422706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*